Page 163 - Haematologica Vol. 107 - September 2022

ARTICLE - Use of aqueous humor in VRL management
X. Wang et al.
7. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679-690.
8. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407.
9. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11(5):285-295.
10. Reichstein D. Primary vitreoretinal lymphoma: an update on pathogenesis, diagnosis and treatment. Curr Opin Ophthalmol. 2016;27(3):177-184.
11. Dawson AC, Williams KA, Appukuttan B, Smith JR. Emerging diagnostic tests for vitreoretinal lymphoma: a review. Clin Exp Ophthalmol. 2018;46(8):945-954.
12. Caraballo JN, Snyder MR, Johnston PB, et al. Vitreoretinal lymphoma versus uveitis: cytokine profile and correlations. Ocul Immunol Inflamm. 2014;22(1):34-41.
13. Kimura K, Usui Y, Goto H, Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56(4):383-389.
14. Davis JL, Miller DM, Ruiz P. Diagnostic testing of vitrectomy specimens. Am J Ophthalmol. 2005;140(5):822-829.
15. Bonzheim I, Sander P, Salmeron-Villalobos J, et al. The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv. 2022 6(3):1598-1607.
16. Lee J, Kim B, Lee H, et al. Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma. Haematologica. 2020;105(9):e458-460.
17. Bonzheim I, Giese S, Deuter C, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126(1):76-79.
18. Xu L, Kim ME, Polski A, et al. Establishing the clinical utility of ctDNA analysis for diagnosis, prognosis, and treatment monitoring of retinoblastoma: the aqueous humor liquid biopsy. Cancers (Basel). 2021;13(6):1282.
19. Miserocchi E, Ferreri AJM, Giuffre C, et al. MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina. 2019;39(4):679-684.
20. Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-843.
21. Shu Y, Wu X, Tong X, et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 2017;7(1):583.
22. Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor ssimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097-3107.
23. Yonese I, Takase H, Yoshimori M, et al. CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential. Eur J Haematol. 2019;102(2):191-196.
24. Nam S, Lim JS. Essential role of interferon regulatory factor 4
(IRF4) in immune cell development. Arch Pharm Res.
2016;39(11):1548-1555.
25. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4
controls plasma cell differentiation and class-switch
recombination. Nat Immunol. 2006;7(7):773-782.
26. De Silva NS, Simonetti G, Heise N, Klein U. The diverse roles of
IRF4 in late germinal center B-cell differentiation. Immunol Rev.
2012;247(1):73-92.
27. Mittrucker HW, Matsuyama T, Grossman A, et al. Pillars article:
requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997. 275: 540-543. J Immunol. 2017;199(11):3717-3720.
28. Yang Y, Shaffer AL, 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723-737.
29. Acquaviva J, Chen X, Ren R. IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 2008;112(9):3798-3806.
30. Blunt MD, Koehrer S, Dobson RC, et al. The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2313-2324.
31. Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol. 2010;23(4):547-558.
32. Tu Q, Hao J, Zhou X, et al. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co- deletion due to juxtaposition to CDKN2A. Oncogene. 2018;37(1):128-138.
33. Nguyen DT, Houillier C, Choquet S, et al. Primary oculocerebral lymphoma: MTX polychemotherapy alone on intraocular disease control. Ophthalmology. 2016;123(9):2047-2050.
34. Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of- concept' iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-cerebral Lymphoma (LOC) network. Eur J Cancer. 2019;117:121-130.
35. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926.
36. Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest Ophthalmol Vis Sci. 2007;48(7):3253-3259.
37. Costopoulos M, Touitou V, Golmard JL, et al. ISOLD: a new highly sensitive interleukin score for intraocular lymphoma diagnosis. Ophthalmology. 2016;123(7):1626-1628.
38. Zhao Y, He JY, Cui JZ, et al. Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing. BMC Cancer. 2020;20(1):690.
39. McEwen AE, Leary SES, Lockwood CM. Beyond the blood: CSF- derived cfDNA for diagnosis and characterization of CNS tumors. Front Cell Dev Biol. 2020;8:45.
Haematologica | 107 September 2022
2162